Please assess the completion status of the following clinical trial:

Trial Title: Effect of Regulated Add -on Sodium Chloride Intake on Stabilization of Serum Lithium Concentration in Bipolar Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 18 -60 years, of either sex with the clinical diagnosis of bipolar disorder (DSM V) who are on maintenance lithium therapy for ≥ 1month and ≤ 6 months.~* Patients with normal serum sodium level (135 -145 mEq/L) and serum lithium in the optimum therapeutic range (\<0.6 mEq/ L or \>0.8 mEq/ L) .~Exclusion Criteria:~* Patients with comorbidities like other psychiatric disorder s, organicity, substance abuse, personality disorder, intellectual disability and other neurotic disorders .~* Patients with any renal, cardiovascular, neurologica l, endocrinal and hepatic dysfunction.~* Patients suffering from diarrhoea, dehydration~* History of any invasive neurosurgical/ non -invasive neuropsychiatric procedure.~* Medication history of psychoactive or central nervous system depressant drugs.~* Patients who are on NSAIDs, ACE inhibitors, antiarrhythmics, diuretics and neuromuscular blocking agents .~* Pregnant and nursing women .~* Patients with drug/alcohol abuse.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Lithium carbonate (Type: ACTIVE_COMPARATOR): Lithium carbonate is prescribed 800-900 mg per day for 12 weeks.
- Add-on Sodium chloride (Type: EXPERIMENTAL): Sodium chloride 1gm per day per will be prescribed along with Lithium carbonate 800-900 mg per day for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).